<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002651</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000064184</org_study_id>
    <secondary_id>SWOG-9346</secondary_id>
    <secondary_id>CAN-NCIC-PR8</secondary_id>
    <secondary_id>CALGB-9594</secondary_id>
    <secondary_id>ECOG-S9346</secondary_id>
    <secondary_id>EORTC-30985</secondary_id>
    <secondary_id>CAN-NCIC-JPR8</secondary_id>
    <secondary_id>INT-0162</secondary_id>
    <nct_id>NCT00002651</nct_id>
  </id_info>
  <brief_title>SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer</brief_title>
  <official_title>Intermittent Androgen Deprivation in Patients With Stage D2 Prostate Cancer, Phase III</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer and Leukemia Group B</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Testosterone can stimulate the growth of prostate cancer cells. Hormone therapy
      may be effective treatment for prostate cancer. It is not yet known which regimen of hormone
      therapy is most effective for stage IV prostate cancer.

      PURPOSE: This randomized phase III trial is studying two different regimens of hormone
      therapy and comparing how well they work in treating men with stage IV prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Compare the survival of patients with metastatic stage IV prostate cancer responsive to
           combined androgen-deprivation therapy (CAD) treated with intermittent vs continuous CAD.

        -  Compare the effects of these treatment regimens on impotence, libido, and
           vitality/fatigue as well as the physical and emotional well-being of these patients.

      Secondary

        -  Compare general symptoms, role functioning, global perception of quality of life, and
           social functioning of patients treated with these regimens.

        -  Assess prostate-specific antigen (PSA) levels after continuous CAD administered before
           randomization and evaluate PSA changes throughout randomized treatment of these
           patients.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to SWOG
      performance status (0-1 vs 2), severity of disease (minimal vs extensive), and prior hormonal
      therapy (neoadjuvant hormonal therapy vs finasteride vs neither).

        -  Induction therapy: Patients receive combined androgen-deprivation (CAD) therapy
           comprising goserelin subcutaneously once a month and oral bicalutamide once daily for 8
           courses (7 months).

        -  Consolidation therapy: Patients are randomized to 1 of 2 consolidation regimens.

             -  Arm I (continuous CAD therapy): Patients continue CAD therapy as in induction
                therapy. Treatment continues in the absence of disease progression.

             -  Arm II (intermittent CAD therapy): Patients undergo observation in the absence of
                rising prostate-specific antigen (PSA) or clinical symptoms of progressive disease.
                Patients with rising PSA or progressive disease begin CAD therapy as in induction
                therapy. Patients whose PSA normalizes after 8 courses return to observation.
                Patients whose PSA does not normalize after 8 courses continue CAD therapy.

      Quality of life is assessed before induction therapy, at 3 months (before consolidation
      therapy), and then at 9 and 15 months.

      Patients are followed every 6-12 months for at least 10 years.

      PROJECTED ACCRUAL: Approximately 1,500 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1995</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Non-inferiority test to determine if intermittent combined androgen deprivation (CAD) overall survival is not substantially worse than continuous CAD overall survival. Specifically, the trial is designed for a one-sided test of the hypothesis that the hazard ratio of intermittent CAD to continuous CAD is 1.2. The assumptions used to compute the trial size are an overall type I error rate of 0.05 and a type II error of 0.10 (power = 0.9).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical Functioning as Measured by the SF-36</measure>
    <time_frame>3 months</time_frame>
    <description>This outcome was scored on a scale of 0 to 100, with higher scores indicating better functioning. Change from Baseline in SF-36 Score at 3 Months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Emotional Functioning as Measured by the SF-36 Mental Health Inventory</measure>
    <time_frame>3 months</time_frame>
    <description>This outcome was scored on a scale of 0 to 100, with higher scores indicating better functioning. Change from Baseline in SF-36 Score at 3 Months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Erectile Dysfunction</measure>
    <time_frame>3 months</time_frame>
    <description>This outcome was assessed by having patients report whether they had erectile dysfunction (a score of 1) or no erectile dysfunction (a score of 0). This analysis looks at change from Baseline to 3 Months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>High Libido</measure>
    <time_frame>3 months</time_frame>
    <description>This outcome was assessed by having patients report whether their interest in sexual activities was very high, high, or moderate (a score of 1) or low or very low (a score of 0). This outcome measure is reporting a change from baseline in the percentage of participants with High Libido at 3 months. &quot;High Libido&quot; is defined as very high, high or moderate interest in sexual activities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vitality</measure>
    <time_frame>3 months</time_frame>
    <description>This outcome was scored on a scale of 0 to 100, with higher scores indicating better functioning. This analysis looks at mean change from Baseline score to 3 Months.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Global Perception of Quality of Life</measure>
    <time_frame>15 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Social Functioning</measure>
    <time_frame>15 months</time_frame>
    <description>Mean of the change in social functioning from randomization</description>
  </other_outcome>
  <other_outcome>
    <measure>Role Functioning</measure>
    <time_frame>15 months</time_frame>
    <description>Mean of the change in role functioning from randomization</description>
  </other_outcome>
  <other_outcome>
    <measure>General Symptoms</measure>
    <time_frame>15 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3040</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Consolidation arm I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients continue CAD therapy comprising goserelin subcutaneously once a month and oral bicalutamide once daily. Treatment continues in the absence of disease progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Consolidation arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo observation in the absence of rising prostate-specific antigen (PSA) or clinical symptoms of progressive disease. Patients with rising PSA or progressive disease begin CAD therapy as in consolidation arm I. Patients whose PSA normalizes after 8 courses return to observation. Patients whose PSA does not normalize after 8 courses continue CAD therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bicalutamide</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Consolidation arm I</arm_group_label>
    <arm_group_label>Consolidation arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>goserelin acetate</intervention_name>
    <description>Given subcutaneously</description>
    <arm_group_label>Consolidation arm I</arm_group_label>
    <arm_group_label>Consolidation arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>clinical observation</intervention_name>
    <description>Patients undergo observation in the absence of rising prostate-specific antigen (PSA) or clinical symptoms of progressive disease.</description>
    <arm_group_label>Consolidation arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed adenocarcinoma of the prostate

               -  Metastatic stage IV (stage D2)

                    -  Any number of bone metastases by bone scan allowed

                    -  Unequivocal visceral organ metastases (liver, brain, or lung) allowed

               -  No suspected second primary tumors unless metastases are histologically
                  confirmed, including special stains (e.g., prostate specific antigen [PSA] and
                  prostatic alkaline phosphatase [PAP])

          -  For entry into late induction therapy:

               -  No more than 1 month from the beginning of antiandrogen therapy to the beginning
                  of luteinizing hormone-releasing hormone (LHRH) agonist therapy

               -  No more than 6 months since initiation of current combined androgen-deprivation
                  therapy (LHRH agonist and antiandrogen)

               -  The effectiveness of the current depot LHRH agonist would not extend beyond 8
                  months after initiation of combined androgen therapy

          -  PSA at least 5 ng/mL

          -  No acute spinal cord compression

        PATIENT CHARACTERISTICS:

        Age:

          -  Adult

        Performance status:

          -  SWOG 0-2

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        Other:

          -  Recovered from any major infection

          -  No active medical illness that would preclude study or limit survival

          -  No other malignancy within the past 5 years except:

               -  Adequately treated basal cell or squamous cell skin cancer

               -  Adequately treated carcinoma in situ of the bladder

               -  Adequately treated other superficial cancer

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No concurrent biological response modifier therapy

        Chemotherapy:

          -  No concurrent chemotherapy

        Endocrine therapy:

          -  See Disease Characteristics

          -  More than 1 year since any prior neoadjuvant or adjuvant hormonal therapy for a
             duration of no more than 4 months

               -  Single or combination therapy allowed

          -  More than 1 year since prior finasteride for prostate cancer for a duration of no more
             than 9 months (less than 6 months for benign prostatic hypertrophy)

          -  Prior or concurrent megestrol for hot flashes allowed

          -  No other concurrent hormonal therapy

        Radiotherapy:

          -  No concurrent radiotherapy other than palliation of painful bone metastases

        Surgery:

          -  No prior bilateral orchiectomy

          -  Recovered from any prior major surgery
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maha Hadi A. Hussain, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Michigan Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bryan J. Donnelly, MD, FRCSC, MSC</last_name>
    <role>Study Chair</role>
    <affiliation>Tom Baker Cancer Centre - Calgary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric J. Small, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Wilding, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Atif Akdas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Marmara University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre - Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute at University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nova Scotia Cancer Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centre of Southeastern Ontario at Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Regional Cancer Program at London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Regional Cancer Centre - General Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odette Cancer Centre at Sunnybrook</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Notre-Dame du CHUM</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill Cancer Centre at McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUS-Hopital Fleurimont</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Cancer Centre at the University of Saskatchewan</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Italy</country>
    <country>Malta</country>
    <country>Netherlands</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Tangen CM, Hussain MH, Higano CS, Eisenberger MA, Small EJ, Wilding G, Donnelly BJ, Schelhammer PF, Crawford ED, Vogelzang NJ, Powell IJ, Thompson IM Jr. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol. 2012 Oct;188(4):1164-9. doi: 10.1016/j.juro.2012.06.046. Epub 2012 Aug 22.</citation>
    <PMID>22921015</PMID>
  </reference>
  <reference>
    <citation>Hussain M, Tangen CM, Higano CS, et al.: Improved overall survival (OS) of patients (pts) with new metastatic prostate cancer (pca): better efficacy or stage migration? Data from SWOG: S9346 and 8894. [Abstract] 2010 Genitourinary Cancers Symposium, March 5-7, 2010, San Francisco, California. A-30, 2010.</citation>
  </reference>
  <reference>
    <citation>Hussain M, Goldman B, Tangen C, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK, Burch PA, Dipaola RS, Crawford ED. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol. 2009 May 20;27(15):2450-6. doi: 10.1200/JCO.2008.19.9810. Epub 2009 Apr 20.</citation>
    <PMID>19380444</PMID>
  </reference>
  <reference>
    <citation>Goldman B, Hussain M, Tangen C, et al.: Prostate-specific antigen progression (PSA-P) as a predictor of overall survival (OS) in patients (pts) with metastatic prostate cancer (PC): data from S9346 and S9916. [Abstract] American Society of Clinical Oncology 2008 Genitourinary Cancers Symposium, Feb 14-16, 2008, San Francisco, CA. A-165, 2008.</citation>
  </reference>
  <reference>
    <citation>Hussain MH, Goldman B, Tangen CM, et al.: Use of prostate-specific antigen progression (PSA-P) to predict overall survival (OS) in patients (pts) with metastatic prostate cancer (PC): data from S9346 and S9916. [Abstract] J Clin Oncol 26 (Suppl 15): A-5015, 2008.</citation>
  </reference>
  <results_reference>
    <citation>Hussain M, Tangen CM, Higano CS, et al.: Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): results of S9346 (INT-0162), an international phase III trial. [Abstract] J Clin Oncol 30 (Suppl 15): A-4, 2012.</citation>
  </results_reference>
  <results_reference>
    <citation>Moinpour C, Berry DL, Ely B, et al.: Preliminary quality-of-life outcomes for SWOG-9346: Intermittent androgen deprivation in patients with hormone-sensitive metastatic prostate cancer (HSM1PC)—phase III. [Abstract] J Clin Oncol 30 (Suppl 15): A-4571, 2012.</citation>
  </results_reference>
  <results_reference>
    <citation>Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D; Southwest Oncology Group Trial 9346 (INT-0162). Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 2006 Aug 20;24(24):3984-90.</citation>
    <PMID>16921051</PMID>
  </results_reference>
  <results_reference>
    <citation>Tangen CM, Hussain M, Wilding G, et al.: Determinants of prostate specific antigen (PSA) normalization in prostate cancer (PCa) patients (pts) treated with androgen deprivation (AD) on Southwest Oncology Group (SWOG) study 9346 (INT-0162). [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-1591, 2003.</citation>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <results_first_submitted>November 15, 2016</results_first_submitted>
  <results_first_submitted_qc>March 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 17, 2017</results_first_posted>
  <last_update_submitted>March 3, 2017</last_update_submitted>
  <last_update_submitted_qc>March 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Bicalutamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Combined Androgen Deprivation (CAD)</title>
          <description>Patients receive goserelin 3.6 mg subcutaneously once a month and oral bicalutamide 50 mg once daily for 7 months.</description>
        </group>
        <group group_id="P2">
          <title>Continuous Hormonal Therapy</title>
          <description>Patients continue to receive goserelin 3.6 mg subcutaneously once a month and oral bicalutamide 50 mg once daily until progression of disease</description>
        </group>
        <group group_id="P3">
          <title>Intermittent Hormonal Therapy</title>
          <description>Patients are cycled between observation periods and Combined Androgen Deprivation (CAD) periods based on PSA results. Patients undergo observation in the absence of rising prostate-specific antigen (PSA) or clinical symptoms of progressive disease. Patients with rising PSA or progressive disease begin CAD therapy (goserelin 3.6 mg subcutaneously once a month and oral bicalutamide 50 mg once daily ). Patients whose PSA normalizes after 8 cycles of CAD treatment return to observation. Patients whose PSA does not normalize after 8 cycles of CAD treatment continue CAD therapy until progression (1 cycle of CAD treatment = 7 months with 8 injections. There are 2 injections in the first month on Days 1 and 29).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Induction</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3040"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Eligible</title>
              <participants_list>
                <participants group_id="P1" count="2950"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Eligible and Began Protocol Therapy</title>
              <participants_list>
                <participants group_id="P1" count="2950"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1697"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1343"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refusal unrelated to adverse event</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progression/relapse</title>
              <participants_list>
                <participants group_id="P1" count="274"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not specified</title>
              <participants_list>
                <participants group_id="P1" count="823"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not eligible</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Consolidation and Randomization</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="867">After induction,patients with stable or declining PSA (≤ 4.0 ng/mL) were eligible for randomization</participants>
                <participants group_id="P3" count="882">After induction,patients with stable or declining PSA (≤ 4.0 ng/mL) were eligible for randomization</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Eligible</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="765"/>
                <participants group_id="P3" count="770"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Assessable for Toxicity</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="732"/>
                <participants group_id="P3" count="702"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="838"/>
                <participants group_id="P3" count="860"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refusal unrelated to adverse event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="75"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progression/relapse</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="295"/>
                <participants group_id="P3" count="298"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="48"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="314"/>
                <participants group_id="P3" count="313"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not eligible</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="102"/>
                <participants group_id="P3" count="112"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized and eligible patients (After induction, Patients with stable or declining PSA levels of 4.0 ng per milliliter or lower at months 6 and 7 were eligible for randomization).</population>
      <group_list>
        <group group_id="B1">
          <title>Continuous Hormonal Therapy</title>
          <description>Patients continue to receive goserelin 3.6 mg subcutaneously once a month and oral bicalutamide 50 mg once daily until progression of disease</description>
        </group>
        <group group_id="B2">
          <title>Intermittent Hormonal Therapy</title>
          <description>Patients are cycled between observation periods and Combined Androgen Deprivation (CAD) periods based on PSA results. Patients undergo observation in the absence of rising prostate-specific antigen (PSA) or clinical symptoms of progressive disease. Patients with rising PSA or progressive disease begin CAD therapy (goserelin 3.6 mg subcutaneously once a month and oral bicalutamide 50 mg once daily ). Patients whose PSA normalizes after 8 cycles of CAD treatment return to observation. Patients whose PSA does not normalize after 8 cycles of CAD treatment continue CAD therapy until progression (1 cycle of CAD treatment = 7 months with 8 injections. There are 2 injections in the first month on Days 1 and 29).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="765"/>
            <count group_id="B2" value="770"/>
            <count group_id="B3" value="1535"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70" lower_limit="39" upper_limit="92"/>
                    <measurement group_id="B2" value="70" lower_limit="39" upper_limit="97"/>
                    <measurement group_id="B3" value="70" lower_limit="39" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="765"/>
                    <measurement group_id="B2" value="770"/>
                    <measurement group_id="B3" value="1535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="571"/>
                    <measurement group_id="B2" value="564"/>
                    <measurement group_id="B3" value="1135"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="177"/>
                    <measurement group_id="B2" value="183"/>
                    <measurement group_id="B3" value="360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="187"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="507"/>
                    <measurement group_id="B2" value="519"/>
                    <measurement group_id="B3" value="1026"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Non-inferiority test to determine if intermittent combined androgen deprivation (CAD) overall survival is not substantially worse than continuous CAD overall survival. Specifically, the trial is designed for a one-sided test of the hypothesis that the hazard ratio of intermittent CAD to continuous CAD is 1.2. The assumptions used to compute the trial size are an overall type I error rate of 0.05 and a type II error of 0.10 (power = 0.9).</description>
        <time_frame>Up to 15 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Consolidation Arm I</title>
            <description>Patients continue CAD therapy comprising goserelin subcutaneously once a month and oral bicalutamide once daily. Treatment continues in the absence of disease progression.
bicalutamide: Given orally
goserelin acetate: Given subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Consolidation Arm II</title>
            <description>Patients undergo observation in the absence of rising prostate-specific antigen (PSA) or clinical symptoms of progressive disease. Patients with rising PSA or progressive disease begin CAD therapy as in consolidation arm I. Patients whose PSA normalizes after 8 courses return to observation. Patients whose PSA does not normalize after 8 courses continue CAD therapy.
bicalutamide: Given orally
goserelin acetate: Given subcutaneously
clinical observation: Patients undergo observation in the absence of rising prostate-specific antigen (PSA) or clinical symptoms of progressive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Non-inferiority test to determine if intermittent combined androgen deprivation (CAD) overall survival is not substantially worse than continuous CAD overall survival. Specifically, the trial is designed for a one-sided test of the hypothesis that the hazard ratio of intermittent CAD to continuous CAD is 1.2. The assumptions used to compute the trial size are an overall type I error rate of 0.05 and a type II error of 0.10 (power = 0.9).</description>
          <units>years</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="765"/>
                <count group_id="O2" value="770"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" lower_limit="5.3" upper_limit="6.4"/>
                    <measurement group_id="O2" value="5.1" lower_limit="4.8" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The overall type I error rate used is 0.05. The type II error rate is 0.10 (power = 0.9). The trial planned for a one-sided test of the hypothesis that the hazard ratio of intermittent CAD to continuous CAD is 1.2. A hazard ratio of 1.0 was used as the specific alternative in the trial size computations. Thus, rejection of the hypothesis will be evidence against the possibility that the intermittent CAD hazard ratio is larger than the continuous CAD hazard ratio by 20% or more.</non_inferiority_desc>
            <p_value>0.15</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.10</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Physical Functioning as Measured by the SF-36</title>
        <description>This outcome was scored on a scale of 0 to 100, with higher scores indicating better functioning. Change from Baseline in SF-36 Score at 3 Months</description>
        <time_frame>3 months</time_frame>
        <population>Only eligible patients with a usable form set for Physical Functioning portion of the SF-36 both at baseline and 3 months were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Continuous Hormonal Therapy</title>
            <description>Patients continue to receive goserelin 3.6 mg subcutaneously once a month and oral bicalutamide 50 mg once daily until progression of disease</description>
          </group>
          <group group_id="O2">
            <title>Intermittent Hormonal Therapy</title>
            <description>Patients are cycled between observation periods and Combined Androgen Deprivation (CAD) periods based on PSA results. Patients undergo observation in the absence of rising prostate-specific antigen (PSA) or clinical symptoms of progressive disease. Patients with rising PSA or progressive disease begin CAD therapy (goserelin 3.6 mg subcutaneously once a month and oral bicalutamide 50 mg once daily ). Patients whose PSA normalizes after 8 cycles of CAD treatment return to observation. Patients whose PSA does not normalize after 8 cycles of CAD treatment continue CAD therapy until progression (1 cycle of CAD treatment = 7 months with 8 injections. There are 2 injections in the first month on Days 1 and 29).</description>
          </group>
        </group_list>
        <measure>
          <title>Physical Functioning as Measured by the SF-36</title>
          <description>This outcome was scored on a scale of 0 to 100, with higher scores indicating better functioning. Change from Baseline in SF-36 Score at 3 Months</description>
          <population>Only eligible patients with a usable form set for Physical Functioning portion of the SF-36 both at baseline and 3 months were included in this analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="469"/>
                <count group_id="O2" value="475"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.74" spread="0.7366"/>
                    <measurement group_id="O2" value="0.09" spread="0.8084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.09</p_value>
            <p_value_desc>The type I error rate used was 0.005 in an attempt to adjust for multiple primary scores being tested.The type II error rate used was 0.10 (power = 0.9).</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.31</ci_lower_limit>
            <ci_upper_limit>3.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Emotional Functioning as Measured by the SF-36 Mental Health Inventory</title>
        <description>This outcome was scored on a scale of 0 to 100, with higher scores indicating better functioning. Change from Baseline in SF-36 Score at 3 Months</description>
        <time_frame>3 months</time_frame>
        <population>Only eligible patients with a usable form set for SF-36 Mental Health Inventory both at baseline and 3 months were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Continuous Hormonal Therapy</title>
            <description>Patients continue to receive goserelin 3.6 mg subcutaneously once a month and oral bicalutamide 50 mg once daily until progression of disease</description>
          </group>
          <group group_id="O2">
            <title>Intermittent Hormonal Therapy</title>
            <description>Patients are cycled between observation periods and Combined Androgen Deprivation (CAD) periods based on PSA results. Patients undergo observation in the absence of rising prostate-specific antigen (PSA) or clinical symptoms of progressive disease. Patients with rising PSA or progressive disease begin CAD therapy (goserelin 3.6 mg subcutaneously once a month and oral bicalutamide 50 mg once daily ). Patients whose PSA normalizes after 8 cycles of CAD treatment return to observation. Patients whose PSA does not normalize after 8 cycles of CAD treatment continue CAD therapy until progression (1 cycle of CAD treatment = 7 months with 8 injections. There are 2 injections in the first month on Days 1 and 29).</description>
          </group>
        </group_list>
        <measure>
          <title>Emotional Functioning as Measured by the SF-36 Mental Health Inventory</title>
          <description>This outcome was scored on a scale of 0 to 100, with higher scores indicating better functioning. Change from Baseline in SF-36 Score at 3 Months</description>
          <population>Only eligible patients with a usable form set for SF-36 Mental Health Inventory both at baseline and 3 months were included in this analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="471"/>
                <count group_id="O2" value="479"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.95" spread="0.6804"/>
                    <measurement group_id="O2" value="1.92" spread="0.7241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>The type I error rate used was 0.005 in an attempt to adjust for multiple primary scores being tested.The type II error rate used was 0.10 (power = 0.9).</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.00</ci_lower_limit>
            <ci_upper_limit>4.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Erectile Dysfunction</title>
        <description>This outcome was assessed by having patients report whether they had erectile dysfunction (a score of 1) or no erectile dysfunction (a score of 0). This analysis looks at change from Baseline to 3 Months.</description>
        <time_frame>3 months</time_frame>
        <population>Only eligible patients with a usable answers regarding erectile dysfunction both at baseline and 3 months were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Continuous Hormonal Therapy</title>
            <description>Patients continue to receive goserelin 3.6 mg subcutaneously once a month and oral bicalutamide 50 mg once daily until progression of disease</description>
          </group>
          <group group_id="O2">
            <title>Intermittent Hormonal Therapy</title>
            <description>Patients are cycled between observation periods and Combined Androgen Deprivation (CAD) periods based on PSA results. Patients undergo observation in the absence of rising prostate-specific antigen (PSA) or clinical symptoms of progressive disease. Patients with rising PSA or progressive disease begin CAD therapy (goserelin 3.6 mg subcutaneously once a month and oral bicalutamide 50 mg once daily ). Patients whose PSA normalizes after 8 cycles of CAD treatment return to observation. Patients whose PSA does not normalize after 8 cycles of CAD treatment continue CAD therapy until progression (1 cycle of CAD treatment = 7 months with 8 injections. There are 2 injections in the first month on Days 1 and 29).</description>
          </group>
        </group_list>
        <measure>
          <title>Erectile Dysfunction</title>
          <description>This outcome was assessed by having patients report whether they had erectile dysfunction (a score of 1) or no erectile dysfunction (a score of 0). This analysis looks at change from Baseline to 3 Months.</description>
          <population>Only eligible patients with a usable answers regarding erectile dysfunction both at baseline and 3 months were included in this analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="450"/>
                <count group_id="O2" value="466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="-7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The type I error rate used was 0.005 in an attempt to adjust for multiple primary scores being tested.The type II error rate used was 0.10 (power = 0.9).</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14</ci_lower_limit>
            <ci_upper_limit>-5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>High Libido</title>
        <description>This outcome was assessed by having patients report whether their interest in sexual activities was very high, high, or moderate (a score of 1) or low or very low (a score of 0). This outcome measure is reporting a change from baseline in the percentage of participants with High Libido at 3 months. &quot;High Libido&quot; is defined as very high, high or moderate interest in sexual activities.</description>
        <time_frame>3 months</time_frame>
        <population>Only eligible patients with a usable answers regarding libido both at baseline and 3 months were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Continuous Hormonal Therapy</title>
            <description>Patients continue to receive goserelin 3.6 mg subcutaneously once a month and oral bicalutamide 50 mg once daily until progression of disease</description>
          </group>
          <group group_id="O2">
            <title>Intermittent Hormonal Therapy</title>
            <description>Patients are cycled between observation periods and Combined Androgen Deprivation (CAD) periods based on PSA results. Patients undergo observation in the absence of rising prostate-specific antigen (PSA) or clinical symptoms of progressive disease. Patients with rising PSA or progressive disease begin CAD therapy (goserelin 3.6 mg subcutaneously once a month and oral bicalutamide 50 mg once daily ). Patients whose PSA normalizes after 8 cycles of CAD treatment return to observation. Patients whose PSA does not normalize after 8 cycles of CAD treatment continue CAD therapy until progression (1 cycle of CAD treatment = 7 months with 8 injections. There are 2 injections in the first month on Days 1 and 29).</description>
          </group>
        </group_list>
        <measure>
          <title>High Libido</title>
          <description>This outcome was assessed by having patients report whether their interest in sexual activities was very high, high, or moderate (a score of 1) or low or very low (a score of 0). This outcome measure is reporting a change from baseline in the percentage of participants with High Libido at 3 months. &quot;High Libido&quot; is defined as very high, high or moderate interest in sexual activities.</description>
          <population>Only eligible patients with a usable answers regarding libido both at baseline and 3 months were included in this analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <p_value_desc>The type I error rate used was 0.005 in an attempt to adjust for multiple primary scores being tested.The type II error rate used was 0.10 (power = 0.9).</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1</ci_lower_limit>
            <ci_upper_limit>36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vitality</title>
        <description>This outcome was scored on a scale of 0 to 100, with higher scores indicating better functioning. This analysis looks at mean change from Baseline score to 3 Months.</description>
        <time_frame>3 months</time_frame>
        <population>Only eligible patients with a usable form set for Vitality both at baseline and 3 months were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Continuous Hormonal Therapy</title>
            <description>Patients continue to receive goserelin 3.6 mg subcutaneously once a month and oral bicalutamide 50 mg once daily until progression of disease</description>
          </group>
          <group group_id="O2">
            <title>Intermittent Hormonal Therapy</title>
            <description>Patients are cycled between observation periods and Combined Androgen Deprivation (CAD) periods based on PSA results. Patients undergo observation in the absence of rising prostate-specific antigen (PSA) or clinical symptoms of progressive disease. Patients with rising PSA or progressive disease begin CAD therapy (goserelin 3.6 mg subcutaneously once a month and oral bicalutamide 50 mg once daily ). Patients whose PSA normalizes after 8 cycles of CAD treatment return to observation. Patients whose PSA does not normalize after 8 cycles of CAD treatment continue CAD therapy until progression (1 cycle of CAD treatment = 7 months with 8 injections. There are 2 injections in the first month on Days 1 and 29).</description>
          </group>
        </group_list>
        <measure>
          <title>Vitality</title>
          <description>This outcome was scored on a scale of 0 to 100, with higher scores indicating better functioning. This analysis looks at mean change from Baseline score to 3 Months.</description>
          <population>Only eligible patients with a usable form set for Vitality both at baseline and 3 months were included in this analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="446"/>
                <count group_id="O2" value="465"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.42" spread="0.7379"/>
                    <measurement group_id="O2" value="-0.11" spread="0.8154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.23</p_value>
            <p_value_desc>The type I error rate used was 0.005 in an attempt to adjust for multiple primary scores being tested.The type II error rate used was 0.10 (power = 0.9).</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.83</ci_lower_limit>
            <ci_upper_limit>3.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Global Perception of Quality of Life</title>
        <time_frame>15 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Social Functioning</title>
        <description>Mean of the change in social functioning from randomization</description>
        <time_frame>15 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Role Functioning</title>
        <description>Mean of the change in role functioning from randomization</description>
        <time_frame>15 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>General Symptoms</title>
        <time_frame>15 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 10 years after registration to Induction</time_frame>
      <desc>Participants were monitored for toxicity every 3 months while on protocol therapy or at more frequent intervals appropriate for that participant, as judged by the treating physician.</desc>
      <group_list>
        <group group_id="E1">
          <title>Continuous Hormonal Therapy</title>
          <description>Patients continue to receive goserelin 3.6 mg subcutaneously once a month and oral bicalutamide 50 mg once daily until progression of disease</description>
        </group>
        <group group_id="E2">
          <title>Intermittent Hormonal Therapy</title>
          <description>Patients are cycled between observation periods and Combined Androgen Deprivation (CAD) periods based on PSA results. Patients undergo observation in the absence of rising prostate-specific antigen (PSA) or clinical symptoms of progressive disease. Patients with rising PSA or progressive disease begin CAD therapy (goserelin 3.6 mg subcutaneously once a month and oral bicalutamide 50 mg once daily ). Patients whose PSA normalizes after 8 cycles of CAD treatment return to observation. Patients whose PSA does not normalize after 8 cycles of CAD treatment continue CAD therapy until progression (1 cycle of CAD treatment = 7 months with 8 injections. There are 2 injections in the first month on Days 1 and 29).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="702"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac ischemia/infarction</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="702"/>
              </event>
              <event>
                <sub_title>Cardiovascular-other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="702"/>
              </event>
              <event>
                <sub_title>LVEF decrease/CHF</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="702"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Flu-like symptoms-other</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="702"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Second primary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="702"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="702"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lung-other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="702"/>
              </event>
              <event>
                <sub_title>Pleural effusions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="702"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="702"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="702"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="665" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="609" subjects_at_risk="702"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="702"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation/bowel obstruction</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="702"/>
              </event>
              <event>
                <sub_title>Diarrhea without colostomy</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="702"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="702"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue/malaise/lethargy</sub_title>
                <counts group_id="E1" subjects_affected="381" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="364" subjects_at_risk="702"/>
              </event>
              <event>
                <sub_title>Pain-other</sub_title>
                <counts group_id="E1" subjects_affected="140" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="131" subjects_at_risk="702"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alkaline phosphatase increase</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="702"/>
              </event>
              <event>
                <sub_title>Creatinine increase</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="702"/>
              </event>
              <event>
                <sub_title>SGOT (AST) increase</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="702"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="702"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="702"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="702"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="239" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="272" subjects_at_risk="702"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="702"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness/light headedness</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="702"/>
              </event>
              <event>
                <sub_title>Sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="702"/>
              </event>
              <event>
                <sub_title>Weakness (motor neuropathy)</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="702"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety/agitation</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="702"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="702"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="123" subjects_at_risk="702"/>
              </event>
              <event>
                <sub_title>Libido loss</sub_title>
                <counts group_id="E1" subjects_affected="262" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="226" subjects_at_risk="702"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary frequency/urgency</sub_title>
                <counts group_id="E1" subjects_affected="141" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="147" subjects_at_risk="702"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile impotence</sub_title>
                <counts group_id="E1" subjects_affected="304" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="256" subjects_at_risk="702"/>
              </event>
              <event>
                <sub_title>Gynecomastia</sub_title>
                <counts group_id="E1" subjects_affected="181" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="158" subjects_at_risk="702"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="702"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="116" subjects_at_risk="702"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="702"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="245" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="176" subjects_at_risk="702"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="511" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="440" subjects_at_risk="702"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="732"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="702"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Statistician</name_or_title>
      <organization>SWOG Statistical Center</organization>
      <phone>206-667-4623</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

